Item 8.01 Other Events
1. Offering of $150 Million of Senior Notes On August 4, we issued a press release announcing that we intend to offer up to $150.0 million aggregate principal amount of senior notes due 2016 in a public offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
2. Pending tender offer for common shares of Standard Diagnostics, Inc. On August 5, 2009 (Korean Standard Time), we announced that we will commence, through an indirect wholly owned subsidiary, an unsolicited cash tender offer to acquire up to 3,236,000 common shares of Standard Diagnostics, Inc., a corporation organized under the laws of South Korea, at a tender offer price equal to 30,000 South Korea Won (US $24.70) per share. The offer will be conducted pursuant to Article 134 of the Korean Financial Investment Services and Capital Markets Act, and a tender offer statement has been or will be filed by our subsidiary with the Korean Financial Services Commission. Daewoo Securities Co., Ltd. is acting as tender offer agent. Standard Diagnostics is a Korean manufacturer and distributor of diagnostic reagents and devices for hepatitis, infectious disease, tumor markers, fertility and drugs of abuse. Standard Diagnostics' common shares are listed on the KOSDAQ stock market under the symbol 066930. The 3,236,000 common shares for which we are soliciting tenders would constitute approximately 40% of the issued common shares of Standard Diagnostics on a fully diluted basis. If we acquire all the shares for which we are soliciting tenders, the aggregate tender offer price in cash would be SKW 97,080 million ($79.9 million). The tender offer will remain open until 3:30 p.m. on August 24, 2009 (Korean Standard Time). Amounts in South Korea Won are also presented in United States Dollars at an assumed exchange rate equal to $1:SKW 0.0008234, which was the New York closing rate of exchange on August 3, 2009 as reported by The Wall Street Journal. Item 9.01 Financial Statements and Exhibits On April 30, 2009, we completed our acquisition of certain assets from ACON Laboratories, Inc. and related entities relating to ACON's lateral flow immunoassay business in the territory consisting of China, Asia Pacific, Latin America, South America, the Middle East, Africa, India, Pakistan, Russia and Eastern Europe, which we refer to as the ACON second territory business. The unaudited statements of assets acquired and liabilities assumed and related statements of revenue and direct expenses of the ACON second territory business for the three months ended March 31, 2009 and 2008 are attached hereto as Exhibit 99.2 and incorporated by reference herein.

Exhibits. Exhibit No. Description 99.1 Press Release dated August 4, 2009 entitled "Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes" 99.2 Unaudited statements of assets acquired and liabilities assumed and related statements of revenue and direct expenses of the ACON second territory business for the three months ended March 31, 2009 and 2008

- 2 -

---

Table of Contents